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Abstract 
Purpose: The purpose of this systematic review is to discuss recent studies and ongoing trials of nab-paclitaxel in 
breast cancer and to examine the potential role of nab-paclitaxel as a backbone for immuno-oncology therapies.
Methods: PubMed and selected congress proceedings were searched for studies of nab-paclitaxel in breast cancer 
published between 2013 and 2015. All phase II and III clinical trials, retrospective analyses, and institutional studies 
were included. Active, ongoing, phase II or III trials on nab-paclitaxel that were listed on ClinicalTrials.gov were also 
included.
Results: Sixty-three studies, including 23 in early-stage and 30 in metastatic breast cancer (some studies not classifia-
ble by setting), were included in this analysis. Trials of neoadjuvant nab-paclitaxel–containing regimens have reported 
pathological complete response rates ranging from 5.7 to 53%. Median overall survival in metastatic breast cancer 
studies ranged from 10.8 to 23.5 months, depending on dose and regimen. Adverse event profiles of nab-paclitaxel 
were generally similar to those reported from previous studies. Several ongoing trials are evaluating nab-paclitaxel in 
the early-stage and metastatic settings, including in combination with immuno-oncology agents.
Conclusions: nab-Paclitaxel continues to demonstrate promising efficacy in breast cancer. Recent studies demon-
strate high pathological complete response rates in early-stage breast cancer, particularly in triple-negative breast 
cancer, an area of high unmet need, and encouraging overall survival in metastatic breast cancer across doses and 
schedules. Ongoing trials will provide further insights into the role of nab-paclitaxel in breast cancer including use as a 
potential backbone chemotherapy agent for immuno-oncology therapies such as checkpoint inhibitors.
Keywords: Breast cancer, Immunotherapy, nab-Paclitaxel, Pathological complete response
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Breast cancer remains the most commonly diagnosed 






mated that 1.7 million new cases of breast cancer were 
diagnosed and that more than half a million women 
died from breast cancer in 2012 [http://www.cancer.org/
acs/groups/content/@research/documents/document/
acspc-044738.pdf]. The majority of patients (61%) present 
with localized disease [http://seer.cancer.gov/statfacts/
html/breast.html]. Regional disease is diagnosed in 32% 
of patients, and 6% present with distant metastatic dis-
ease [http://seer.cancer.gov/statfacts/html/breast.html]. 
The overall 5-year survival for all stages combined is 89% 
[http://seer.cancer.gov/statfacts/html/breast.html]. How-
ever, survival rates vary by stage. Localized disease is asso-
ciated with a 5-year survival rate of 99%, regional disease 
is associated with a 5-year survival rate of 85%, and met-
astatic disease is associated with a 5-year survival rate of 
26% [http://seer.cancer.gov/statfacts/html/breast.html].
Treatments for localized breast cancer consist of sur-
gical resection with or without radiation therapy [1]. 
Neoadjuvant chemotherapy is recommended for large 
tumors (stage IIA-B or T3N1M0). The primary approach 
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for managing metastatic breast cancer (MBC) is systemic 
therapy, consisting of cytotoxic chemotherapy, endo-
crine therapy for hormone receptor–positive disease, and 
HER2-targeted agents for HER2-positive cancers. Many 
of the neoadjuvant, adjuvant, and metastatic chemother-
apy regimens preferred by the National Comprehensive 
Cancer Network include paclitaxel [1]. One disadvan-
tage of paclitaxel is the development of hypersensitivity 
reactions to the solvent, Kolliphor EL (formerly called 
Cremophor EL) [2]. Nanoparticle albumin-bound pacli-
taxel (nab®-paclitaxel, Celgene Corporation, Summit, 
NJ) is solvent-free, minimizing hypersensitivity reactions 
and potentially other solvent-related toxicities, such as 
neutropenia [3–5]. Due to minimal risk of hypersensi-
tivity, premedication with prophylactic steroids is not 
required [3, 4]. Another advantage of nab-paclitaxel vs 
standard paclitaxel is the increased rate of transport 
across endothelial cell layers, greater and faster tissue 
penetration, and slower elimination of paclitaxel [6–8]. 
nab-Paclitaxel also demonstrates increased intratumoral 
delivery and retention, resulting in 33% higher intratu-
moral drug concentrations [6]. Compared with paclitaxel, 
nab-paclitaxel yields a 10-fold higher mean maximal con-
centration of free paclitaxel [8].
nab-Paclitaxel is currently approved for locally 
advanced or metastatic non-small cell lung cancer, meta-
static pancreatic cancer, and MBC that has progressed on 
combination chemotherapy or relapsed within 6 months 
of adjuvant chemotherapy [2]. The approval in MBC was 
based on a randomized phase III trial of nab-paclitaxel 
260 mg/m2 vs paclitaxel 175 mg/m2 every 3 weeks (q3w). 
nab-Paclitaxel demonstrated a significantly higher over-
all response rate (ORR; 33 vs 19%; P = 0.001) and longer 
time to tumor progression (23 vs 17 weeks; hazard ratio 
[HR], 0.75; P =  0.006) vs paclitaxel in the intention-to-
treat (ITT) population [5]. Overall survival (OS) was not 
significantly different between the 2 treatment groups 
in the ITT population; however, in the second- or later-
line setting, OS was significantly longer for nab-pacli-
taxel vs paclitaxel (median, 56 vs 47  weeks; HR, 0.73; 
P  =  0.024). Significantly less grade 4 neutropenia (9 vs 
22%; P  <  0.001) and more grade 3 sensory neuropathy 
(10 vs 2%; P < 0.001) were reported with nab-paclitaxel 
[5]. Grade 3 sensory neuropathy in patients who received 
nab-paclitaxel improved to a lower grade after a median 
of 22 days of treatment interruption.
Recent studies have examined nab-paclitaxel in 
early-stage breast cancer, primarily as a neoadjuvant 
agent. Studies also continue to evaluate the efficacy 
of nab-paclitaxel in MBC in combination and across 
doses and schedules. This review summarizes data 
from recent studies of nab-paclitaxel across breast 
cancer settings, discusses ongoing trials, and provides 
perspectives on the future role of nab-paclitaxel in 
breast cancer.
Methods
PRISMA guidelines were followed in this system-
atic review. PubMed was searched for articles pub-
lished between January 1, 2013 and February 28, 2016. 
Abstracts from the American Society for Clinical Oncol-
ogy (ASCO) annual meeting and the ASCO Breast Can-
cer Symposium 2013–2015 were included. The entry 
terms for the search were “nab-paclitaxel” and “breast.” 
Abstracts from the 2014 European Breast Cancer Con-
ference and the 2013–2015 San Antonio Breast Cancer 
Symposium proceedings were searched using the term 
“nab-paclitaxel.” Phase II and III clinical trials, retrospec-
tive analyses, and institutional studies were included. 
Duplicate studies, topic reviews, case studies, nonhu-
man or preclinical studies, and non-English articles were 
excluded. One article in PubMed was embargoed and 
inaccessible.
Results
The publication selection process is depicted in Fig.  1. 
Twenty-three studies of nab-paclitaxel in early-stage 
breast cancer were retrieved, including 21 neoadju-
vant and 2 adjuvant studies. Three post hoc analyses 
of previous neoadjuvant trials were included in the 21 
retrieved neoadjuvant studies. Studies of neoadjuvant 
nab-paclitaxel in early-stage breast cancer are presented 
in Table  1. There were also 30 studies of nab-paclitaxel 
in MBC, including 3 health economic analyses. Studies 
of nab-paclitaxel in MBC that reported progression-free 
survival (PFS) or OS are presented in Table 2. Only stud-
ies with  ≥50 patients are detailed in the text; however, 
all reports on early-stage HER2+ disease were included 
because of the small number of studies.
Studies of nab‑paclitaxel in early‑stage breast cancer
Unselected (all subtypes)
Among 7 phase II and III studies of neoadjuvant nab-
paclitaxel (majority administered weekly) that did not 
select for specific disease subtype, the pathological com-
plete response (pCR) rate ranged from 22 to 40%; 4 phase 
II studies included <50 patients (Table 1).
A trend toward benefit for stage II disease was 
observed with nab-paclitaxel 125  mg/m2 once weekly 
(qw) plus carboplatin vs paclitaxel 80  mg/m2 qw plus 
carboplatin in a phase II trial with a pCR rate of 36.8 
vs 15.8% (odds ratio [OR], 3.11; 95% CI 0.963–10.053; 
P = 0.051); however, no such trend was observed in the 
overall population [9]. More grade 4 neutropenia was 
observed with nab-paclitaxel than with paclitaxel (56.7 vs 
21.1%; P < 0.001).
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A phase II trial of nab-paclitaxel 260 mg/m2 q3w and 
cyclophosphamide 600  mg/m2 followed by fluorouracil, 
epirubicin, and cyclophosphamide (FEC) q3w for oper-
able breast cancer resulted in a pCR rate of 37% (95% 
CI 24–50%) [10]. Hormone receptor–positive/HER2-
negative tumors demonstrated the lowest pCR rate (8%), 
whereas all other molecular subgroups had pCR rates 
ranging from 56 to 63%. Hormone receptor negativity 
(HR, 11.9; 95% CI 2.8–52.6; P = 0.001) and HER2 positiv-
ity (HR, 6.8; 95% CI 1.5–32.0; P = 0.015) were independ-
ent predictors of pCR.
The large phase III GeparSepto trial compared neoadju-
vant paclitaxel 80 mg/m2 qw vs nab-paclitaxel 125 mg/m2 
(150  mg/m2 before amendment) qw followed by epiru-
bicin and cyclophosphamide (EC) for early-stage breast 
cancer, with trastuzumab plus pertuzumab added for 
HER2-positive cancers [11]. The original dose of nab-
paclitaxel (150  mg/m2) was amended to 125  mg/m2 
due to the frequency of treatment discontinuations and 
sensory neuropathy. Overall, patients achieved a sig-
nificantly higher pCR rate with nab-paclitaxel vs pacli-
taxel (38.4 vs 29.0%; P < 0.001). The higher pCR rate for 
nab-paclitaxel vs paclitaxel was maintained in the set of 
patients who received treatment after the nab-paclitaxel 
dose amendment (41.4 vs 32.4%; P = 0.013). The largest 
difference between treatment arms was observed in the 
triple-negative breast cancer (TNBC) subgroup, with 
nab-paclitaxel achieving a pCR rate of 48.2 vs 26.3% with 
paclitaxel (P < 0.001).
The pCR rates in 4 phase II neoadjuvant studies of nab-
paclitaxel for the treatment of early-stage breast cancer 
of unselected subtype ranged from 22 to 40%, with 71 
to 77.5% of patients having breast-conserving surgery 
[9–12].
HER2‑negative or TNBC
Nine studies of nab-paclitaxel in early-stage HER2-neg-
ative breast cancer or TNBC were retrieved. The overall 
pCR rate ranged from 5.7 to 53% (Table 1). Most of these 
were combination studies.
The phase II Nabrax GEICAM study of neoadjuvant 
nab-paclitaxel 150 mg/m2 the first 3 of 4 weeks (qw 3/4) 
in patients with ER-positive, HER2-negative breast can-
cer demonstrated an ORR of 76.5% [13]. A residual can-
cer burden (RCB) score of 0 + 1 was achieved by 24.7% of 
the treated population (n = 81), and the rate of conver-
sion to breast-conserving surgery was 40%.
The phase II SWOG S0800 trial evaluated the back-
bone neoadjuvant regimen of nab-paclitaxel 100 mg/m2 
qw with dose-dense doxorubicin plus cyclophosphamide 
(AC) ± bevacizumab for the treatment of HER2-negative 
locally advanced or inflammatory breast cancer [14]. 
The overall pCR rate was 28%, with a significantly higher 
pCR rate reported in the bevacizumab vs non-bevaci-
zumab arm (36 vs 21%; P =  0.021). In hormone recep-
tor–positive disease, the difference in pCR rate between 
bevacizumab and no bevacizumab was not significant 
(25 vs 18%; P =  0.41). However, patients with hormone 
receptor–negative tumors demonstrated a significantly 
improved pCR rate with bevacizumab (59 vs 28%; 
P  =  0.014). In addition, a significantly improved pCR 
rate was achieved with bevacizumab vs no bevacizumab 
in the locally advanced breast cancer group (37 vs 22%; 
P = 0.035).
Another trial that evaluated a nab-paclitaxel–con-
taining backbone regimen was the phase II TBCRC 008 
study, which compared 12  weeks of neoadjuvant carbo-
platin, nab-paclitaxel 100  mg/m2 qw, and vorinostat vs 
carboplatin, nab-paclitaxel 100  mg/m2 qw, and placebo 
for operable, stage II–III, HER2-negative breast can-
cer [15]. Similar pCR rates were reported for both arms 
(vorinostat, 25.8% vs placebo, 29.0%). The pCR rates in 
patients with TNBC were 41.7% with vorinostat and 
58.3% with placebo.
The phase II ADAPT trial was designed as an umbrella 
trial in which patients with early-stage breast cancer 
Reports idenfied from PubMed and 
congress searches
n = 166
Reports aer removing duplicates and 
excluding reviews, preclinical studies, 
and case studies
n = 96
Reports aer excluding non-English 
studies, studies of other diseases, and 
an embargoed study 
n = 63
(manuscripts n = 30;
abstracts/posters n = 33)
Fig. 1 Schematic of literature search
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had 2 sequential core biopsies during neoadjuvant ther-
apy (baseline and 3  weeks after treatment initiation) 
to assess early biomarker changes and guide adjuvant 
therapy selection [16]. Patients were assigned to 1 of 4 
subtrials based on molecular subtyping. One subtrial 
was the ADAPT-TN trial, which evaluated a backbone 
of neoadjuvant nab-paclitaxel 125  mg/m2 given the 
first 2 of 3  weeks (qw 2/3) with either carboplatin or 
gemcitabine in patients with TNBC [17, 18]. The pCR 
rate differed significantly between arms (carboplatin, 
47.4% vs gemcitabine, 29.7%; P = 0.0045). Patients who 
received nab-paclitaxel plus gemcitabine vs nab-pacli-
taxel plus carboplatin experienced a significantly higher 
frequency of dose reductions (20.6 vs 11.9%; P = 0.03), 
treatment-related severe adverse events (13 vs 5%; 
P = 0.02), grade 3–4 infections (6.1 vs 1.3%; P = 0.04), 
Table 2 Progression-free and overall survival in recent clinical studies of nab-paclitaxel in metastatic breast cancer
No HER2+ studies reported OS or PFS
AUC area under the curve, bev bevacizumab, carbo carboplatin, HER2 human epidermal growth factor receptor 2, ITT intention to treat, MBC metastatic breast cancer, 
nab-P nab-paclitaxel, NR not reported, OS overall survival, PFS progression-free survival, PICN paclitaxel injection concentrate for nanodispersion, qw weekly, qw 3/4 
first 3 of 4 weeks, q2w every 2 weeks, q3w every 3 weeks, q4w every 4 weeks, TNBC triple-negative breast cancer
a Bev was optional per protocol amendment; 97% of patients received bev
b Median OS was 26.5 months for comparison vs nab-P
Study, author, 
year
Type of study N (ITT) Patient popula‑
tion or stage 
of disease




Unselected (all subtypes; n = 5)
 CALGB 40502, 
Rugo, 2015 [30]
Phase III 799 Stage IIIC or IV 
locally recurrent 
or MBC
First Beva + paclitaxel 
90 mg/m2 qw 3/4
11 27.4b
Bev + nab-P 
150 mg/m2 qw 
3/4
9.3 23.5
Bev + ixabepilone 
16 mg/m2 qw 3/4
7.4 23.6
 Jain, 2016 [32] Phase II/III 180 MBC Multiple (all lines) nab-P 260 mg/m2 
q3w
7.8 NR
PICN 260 mg/m2 
q3w
5.3 NR
PICN 295 mg/m2 
q3w
8.1 NR
 Sun, 2014 [31] Phase II 73 MBC Multiple (all lines) nab-P 125 mg/m2 
qw 3/4 → cispl-
atin 75 mg/m2 
q4w
9.8 26.9
 Dent, 2013 [63] Retrospective 43 MBC Multiple (all lines) nab-P 260 mg/m2 
q3w
NR 10.8
nab-P 100 mg/m2 
qw 3/4
13.6
 Aigner, 2013 [64] Retrospective 36 MBC Multiple (all lines) nab-P 100-150  
mg/m2 qw
7.5 14.2
HER2− or TNBC (n = 4)
 TBCRC 019, 
Forero-Torres, 
2015 [37]
Phase II 64 Metastatic TNBC Multiple (all lines) nab-P 100 mg/m2 
qw 3/4 + tigatu-




nab-P 100 mg/m2 
qw 3/4
3.7
 Palumbo, 2015 
[38]
Phase II 52 HER2− MBC Second nab-P 260 mg/m2 
q3w
8.9 Not yet reached
 Hamilton, 2013 
[65]
Phase II 34 Metastatic TNBC First nab-P 100 mg/m2 
qw 3/4 + carbo 
AUC 2 qw 
3/4 + bev 10  
mg/kg q2w
9.2 NR
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and alanine aminotransferase elevations (11.7 vs 3.3%; 
P = 0.01).
Docetaxel 75  mg/m2 q3w was compared with nab-
paclitaxel 100 mg/m2 qw 3/4 followed by FEC with epiru-
bicin at 100 mg/m2 for stage II–III, HER2-negative breast 
cancer [19]. The overall pCR rate was 17%, with a higher 
pCR rate of 30% in patients with TNBC. Another trial 
that evaluated sequential nab-paclitaxel 260 mg/m2 q3w 
and EC demonstrated a pCR rate of 5.7% in patients with 
stage II–III HER2-negative breast cancer (N = 53) [20].
HER2‑positive
Three studies of nab-paclitaxel in early-stage HER2-pos-
itive breast cancer demonstrated highly consistent pCR 
rates, ranging from 45 to 49% (Table 1). Neoadjuvant car-
boplatin, nab-paclitaxel, and trastuzumab treatment in 
patients with stage II–III HER2-positive tumors resulted 
in a pCR rate of 45% in 55 evaluable patients, and a pCR 
plus RCB I rate of 50% in the ITT population [21]. A 
pCR rate of 52% was achieved in patients with ER-neg-
ative disease compared with a pCR rate of 40% in those 
with ER-positive disease. A phase II trial of neoadjuvant 
anthracycline followed by nab-paclitaxel 260 mg/m2 q3w 
plus trastuzumab for operable HER2-positive breast can-
cer reported a pCR rate of 49% in the treated popula-
tion [22]. Subgroup analysis demonstrated a higher pCR 
rate of 71% in patients with ER-negative tumors vs 36% 
in those with ER-positive disease. Similar results were 
achieved with neoadjuvant nab-paclitaxel 260  mg/m2 
every 2 weeks (q2w) followed by vinorelbine and trastu-
zumab for stage I–III HER2-positive breast cancer [23]. 
An overall pCR rate of 48.1% was reported, with a pCR 
rate of 68.8% in the hormone receptor–negative popula-
tion and a pCR rate of 18.2% in the hormone receptor–
positive population (n = 11).
Post hoc analyses
Recent post hoc biomarker analyses were reported for 
the Brown University Oncology Group trials BR-211A 
(NCT00723125), which evaluated bevacizumab, nab-
paclitaxel, and carboplatin in stage II–III HER2-nega-
tive breast cancer, and BR-211B (NCT00617942), which 
examined trastuzumab, nab-paclitaxel, and carboplatin in 
stage II–III HER2-positive breast cancer [24–26]. Among 
patients with HER2-negative early-stage breast cancer 
in BR-211A, a strong correlation was found between 
triple-negative status and pCR rate after treatment with 
bevacizumab, nab-paclitaxel, and carboplatin (P < 0.001) 
[25]. In the BR-211B trial, the pCR rate was 50% among 
20 patients for whom evaluable tissues and pCR data 
were available, and a strong correlation was reported for 
high baseline HER2 and pCR (P =  0.002) [24]. In addi-
tion, higher baseline levels of stromal tumor-infiltrating 
lymphocytes (sTILs) (median, 35 vs 25%; P  =  0.018) 
were found in patients with HER2-positive tumors who 
achieved RCB 0 + 1 (defined as responders) vs RCB 2 + 3 
(defined as nonresponders), respectively [26].
Adjuvant treatment with nab‑paclitaxel
Two studies of adjuvant nab-paclitaxel in early-stage dis-
ease were retrieved. The combination of nab-paclitaxel 
100  mg/m2 and capecitabine was compared with EC 
or cyclophosphamide, methotrexate, and fluorouracil 
(CMF) as adjuvant therapy for early-stage breast cancer 
in nonfrail elderly patients (age ≥65 years) in the phase 
II ICE II-GBG 52 trial [27]. After a median follow-up of 
almost 23  months, no significant difference in OS was 
observed between treatment arms (HR, 1.18; 95% CI 
0.52–2.66). A greater percentage of patients experienced 
treatment discontinuations with nab-paclitaxel plus 
capecitabine than EC/CMF (35.8 vs 6.6%; P < 0.001). In 
both arms, the main reasons for discontinuation were 
adverse events followed by investigator or patient deci-
sion; however, grade ≥3 toxicities were less frequent with 
nab-paclitaxel plus capecitabine than EC/CMF (64.8 vs 
90.9%; P < 0.001). Grade ≥3 hematologic events were less 
common (22.3 vs 88.4%; P  <  0.001) and grade ≥3 non-
hematologic events were more common (58.5 vs 18.7%; 
P  <  0.001) with nab-paclitaxel plus capecitabine than 
with EC/CMF. The authors suggested that tolerability 
might have been better if a lower capecitabine dose were 
used in the nab-paclitaxel plus capecitabine arm.
Ongoing trials in early‑stage breast cancer
The ongoing phase III GAIN-2 study (NCT01690702; 
planned N  =  2886) compares nab-paclitaxel on a less 
common dose-dense schedule (330 mg/m2 q2w) plus EC 
vs EC followed by docetaxel using invasive disease-free 
survival as the primary endpoint (https://clinicaltrials.
gov/ct2/show/NCT01690702, [28]). Among the 1473 
patients who have been randomized, those in the nab-
paclitaxel arm demonstrated higher rates of grade  ≥3 
febrile neutropenia (12 vs 8%) and peripheral sensory 
neuropathy (83 vs 68%) and required more dose reduc-
tions due to hematologic toxicities (30 vs 10%; P < 0.001).
The ETNA trial, another ongoing phase III study 
(NCT01822314; planned N = 632), is evaluating single-
agent nab-paclitaxel 125  mg/m2 qw 3/4 vs paclitaxel 
90  mg/m2 qw 3/4 as neoadjuvant therapy for high-risk 
HER2-negative breast cancer [https://clinicaltrials.gov/
ct2/show/NCT01822314]. In each arm, patients will 
receive AC, EC, or FEC after initial taxane therapy. The 
primary endpoint is pCR.
Another ongoing phase III trial (Nordic trip, N = 1800), 
will provide additional information about the poten-
tial benefit of nab-paclitaxel plus EC as a treatment for 
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early TNBC [29]. Patients will be randomized to receive 
adjuvant or neoadjuvant treatment in 1 of 3 arms: nab-
paclitaxel followed by EC, nab-paclitaxel plus capecit-
abine followed by EC plus capecitabine, or nab-paclitaxel 




Four studies of nab-paclitaxel in MBC of unselected sub-
type reported median OS ranging from 10.8 months with 
nab-paclitaxel 260 mg/m2 q3w to 26.9 months with nab-
paclitaxel 125  mg/m2 qw 3/4 combined with cisplatin 
(Table 2).
The phase III CALGB 40502 trial evaluated first-line 
bevacizumab combined with paclitaxel 90  mg/m2, nab-
paclitaxel 150 mg/m2, or ixabepilone 16 mg/m2 qw 3/4 for 
locally recurrent or metastatic breast cancer [30]. A pro-
tocol amendment made the use of bevacizumab optional; 
however, 97% of patients had already received bevaci-
zumab at that time. The majority (93%) of patients had 
HER2-negative disease. Median PFS (primary endpoint) 
was 11 months for the paclitaxel arm vs 9.3 months with 
nab-paclitaxel (HR, 1.20; 95% CI 1.00–1.45; P =  0.054) 
and 7.4  months with ixabepilone (HR, 1.59; 95% CI 
1.31–1.93; P  <  0.001). Median OS significantly differed 
between ixabepilone and paclitaxel (23.6 vs 27.4 months, 
respectively; HR, 1.31; 95% CI 1.03–1.66; P  =  0.027), 
but not between nab-paclitaxel and paclitaxel (23.5 vs 
26.5  months, respectively; HR, 1.17; 95% CI 0.92–1.47; 
P  =  0.20). Grade  ≥3 nonhematologic toxicities were 
more common in the nab-paclitaxel vs paclitaxel arm 
(65 vs 49%; P < 0.001), with grade ≥2 sensory neuropa-
thy affecting more patients treated with nab-paclitaxel vs 
paclitaxel (54 vs 46%; P = 0.031). Compared with pacli-
taxel, nab-paclitaxel demonstrated worse hematologic 
and nonhematologic toxicity (both, P  <  0.001). Ixabepi-
lone caused less hematologic toxicity (P = 0.004) but not 
significantly different nonhematologic toxicity (P = 0.14) 
than paclitaxel. Dose reductions occurred more fre-
quently and earlier in the nab-paclitaxel arm: by cycle 3, 
45% of patients receiving nab-paclitaxel had undergone 
a dose reduction compared with 15% of those receiving 
paclitaxel and 15% of those receiving ixabepilone. Only 
28% of patients received full-dose nab-paclitaxel at cycle 
5 vs 76% of patients receiving paclitaxel and 65% receiv-
ing ixabepilone.
A phase II trial of nab-paclitaxel 125  mg/m2 qw 3/4 
and cisplatin for MBC reported an ORR (primary end-
point) of 67.1%, with an 80.6% ORR in the first-line 
setting and an 80% ORR for those who were not pre-
viously treated with taxanes [31]. The median PFS was 
9.8  months (95% CI 8.1–11.6  months) by investigator 
assessment, and median OS was 26.9  months. Com-
pared with patients who were pretreated with taxa-
nes, those who had not previously received taxanes 
demonstrated longer PFS (median, 8.5 vs 11.2 months; 
P  =  0.009) by investigator assessment and longer 
OS (median, not reached vs 16.7  months; P  <  0.001). 
There were no significant differences in PFS according 
to molecular subtype. Treatment was well tolerated in 
most patients, with neutropenia being the most com-
mon cause for dose adjustment. Grade  ≥3 neutrope-
nia was the most common hematologic adverse event, 
affecting 84.9% of patients.
A randomized phase II/III trial of women with refrac-
tory MBC compared nab-paclitaxel 260  mg/m2 q3w 
with paclitaxel concentrate for nanodispersion (PICN) 
260 or 295  mg/m2 q3w [32]. Comparing the equal-dose 
regimens of nab-paclitaxel and PICN, ORR and PFS were 
numerically greater for nab-paclitaxel vs PICN (ORR, 43 
vs 35%; PFS, median, 7.8 vs 5.3 months [P not significant 
for either]). ORR and PFS were not significantly differ-
ent for higher-dose PICN vs lower-dose PICN or vs nab-
paclitaxel. The lower-dose PICN arm had lower rates of 
grade ≥3 adverse events compared with the higher-dose 
PICN arm and the nab-paclitaxel arm.
A number of regional retrospective analyses have also 
been conducted recently on the use of nab-paclitaxel 
for the treatment of unselected MBC. A retrospective 
analysis of patients with breast cancer in British Colum-
bia who received nab-paclitaxel from 2007 to 2011 was 
performed [33]. Most patients had metastatic disease, 
and 2 had regional relapse only. Approximately one-
fourth of patients had prior taxane exposure. Time to 
relapse was significantly shorter in patients with prior 
exposure to adjuvant taxanes vs those without (median, 
2.7 vs 4.5 years, P < 0.001). No significant differences in 
time to treatment failure (defined as time from first to 
last cycle of nab-paclitaxel) or dose reduction rates were 
found between these 2 groups. Thus, nab-paclitaxel may 
result in clinical benefit in patients with MBC regard-
less of whether they have had prior taxane exposure. A 
retrospective German survey of national chemotherapy 
practices demonstrated that nab-paclitaxel was used 
less frequently than paclitaxel and docetaxel for first-line 
treatment of MBC [34]. However, retrospective analy-
sis of a US claims database of patients with MBC who 
were treated with taxanes (n = 2599 docetaxel; n = 1643 
paclitaxel; n  =  261 nab-paclitaxel) demonstrated that 
patients remained on nab-paclitaxel 50% longer than 
on other taxanes (127 vs 85 days; P < 0.05), possibly due 
to lower incidence of discontinuation for neutropenia 
with nab-paclitaxel vs docetaxel or paclitaxel (6.9% vs 
docetaxel, 29.4% or paclitaxel, 17.5%; P  <  0.001) [35]. A 
separate analysis of a US claims database revealed that 
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nab-paclitaxel was most often administered as second- 
or later-line therapy, as monotherapy, or on a weekly 
schedule [36].
HER2‑negative or TNBC
A phase II trial of nab-paclitaxel 100  mg/m2 qw 3/4 
with or without anti–death receptor 5 monoclonal anti-
body tigatuzumab (10  mg/kg loading, 5  mg/kg q2w) 
was performed in patients with metastatic TNBC [37]. 
ORR was 28% in the combination arm vs 38% in the 
nab-paclitaxel–alone arm. PFS was not significantly dif-
ferent between arms (median, 3.7 months for nab-pacli-
taxel monotherapy vs 2.8  months for the combination; 
P = 0.3152). Five patients in the combination arm dem-
onstrated long-term PFS (334–1025+  days) compared 
with 1 patient in the nab-paclitaxel arm (1004+ days).
There was one study of nab-paclitaxel in patients with 
HER2-negative MBC (unselected for hormone receptor 
status) that reported median PFS [38]. None of the stud-
ies on HER2-negative breast cancer or TNBC reported 
OS.
A prospective trial of second-line nab-paclitaxel 
260  mg/m2 q3w in patients with HER2-negative MBC 
with prior taxane exposure reported an ORR of 48% (95% 
CI 31.5–61.3%) and a median PFS of 8.9 months (95% CI 
8.0–11.6 months; range, 5–21+ months) [38]. Response 
rate by subgroup demonstrated a higher response in 
TNBC (68.8%) vs other subgroups (ER+/PR−, 55.6%; 
ER−/PR+, 50.0%; ER+/PR+, 32.0%). Median OS was not 
reached.
Health economic analyses
Three cost-effectiveness analyses compared nab-pacli-
taxel with other taxanes in patients with MBC.
The Spanish COSTABRAX cost-effectiveness analysis 
demonstrated that nab-paclitaxel q3w was cost-effective 
compared with paclitaxel q3w as a second-line treatment 
for MBC [39]. Efficacy data from the phase III CA012 
trial were used in a Markov model expanded to a time 
horizon of 5 years. The cost of life-year gained with nab-
paclitaxel q3w vs paclitaxel q3w was €11,088, and the 
cost per quality-adjusted life-year (QALY) gained was 
€17,808. Compared with paclitaxel qw, nab-paclitaxel 
q3w showed a savings of €711 per patient. Another study 
combined cost data in China with a meta-analysis of 10 
randomized phase III trials of nab-paclitaxel 260 mg/m2 
q3w or docetaxel 100  mg/m2 q3w in comparison with 
paclitaxel 175  mg/m2 q3w [40]. The cost per course of 
treatment was $19,752 for nab-paclitaxel, $8940 for 
paclitaxel, and $13,741 for docetaxel. The cost per QALY 
gained for nab-paclitaxel vs docetaxel as alternatives to 
paclitaxel was $57,900 vs $130,600. Thus, nab-pacli-
taxel appeared to be a more cost-effective alternative to 
docetaxel as initial therapy for MBC in a Chinese health-
care setting. The Italian COSTANza study, which used 
a Markov model, also suggested that nab-paclitaxel was 
cost-effective, with a gain of 0.165 QALY compared with 
paclitaxel [41].
A recent questionnaire-based study of healthcare 
providers (N  =  22) in Sweden indicated that mean 
infusion times for nab-paclitaxel vs paclitaxel were 
42.1 ± 20.7 vs 104.3 ± 43.3 min, respectively [42]. Total 
patient times in clinic per infusion were 82.2  ±  40.9 
and 183.9 ± 34.8 min, respectively. The study suggested 
that the corresponding time required for a 12-week 
treatment of nab-paclitaxel q3w, nab-paclitaxel qw, 
and paclitaxel qw would be 2.8, 8.4, and 20.9 h, respec-
tively. The corresponding time for patient hospital visits 
would be 5.5, 16.4, and 36.8 h, respectively. Thus, nab-
paclitaxel may require less time for drug administration, 
potentially reducing cost.
Ongoing trials in MBC
Table 3 lists selected ongoing trials of nab-paclitaxel regi-
mens for the treatment of MBC. There are several ongo-
ing trials evaluating combinations of nab-paclitaxel with 
HER2-targeted agents for the treatment of metastatic 
HER2-positive breast cancer. The single-arm phase III 
PERUSE trial (NCT01572038; planned N = 1500) is eval-
uating the safety of first-line pertuzumab combined with 
trastuzumab and a taxane of the investigator’s choice, as 
its primary endpoint, in patients with metastatic or locally 
recurrent HER2-positive breast cancer [https://clinicaltri-
als.gov/ct2/show/NCT01572038]. Secondary endpoints 
include PFS, OS, ORR, and quality of life. Interim safety 
results indicated that grade  ≥3 adverse events occurred 
in 53.4% of patients in the docetaxel group (n  =  320), 
41.1% in the paclitaxel group (n = 331), and 26.7% in the 
nab-paclitaxel group (n  =  45) [43]. The most common 
grade  ≥3 toxicities included neutropenia (approximately 
12, 6, and 2% in docetaxel, paclitaxel, and nab-paclitaxel 
groups, respectively) and diarrhea (approximately 9, 6, 
and 6%). The phase IIIb SAPPHIRE trial (NCT02019277; 
N  =  50) is evaluating the safety and efficacy of trastu-
zumab combined with intravenous pertuzumab and a 
taxane of investigator’s choice in patients with metastatic 
HER2-positive breast cancer [44, 45]. Interim results 
showed that 50 patients had been enrolled, with the major-
ity (72%) receiving nab-paclitaxel as the taxane of choice. 
Grade ≥3 adverse events were reported in 52% of patients, 
although toxicities were not categorized according to type 
of taxane received. In addition, the phase I/II STELA trial 
(NCT02073916; planned N  =  45) will combine trastu-
zumab emtansine (T-DM1), nab-paclitaxel, and lapatinib 
to treat metastatic HER2-positive MBC (https://clinicaltri-
als.gov/ct2/show/NCT02073916, [46]).
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Table 3 Selected ongoing studies of nab-paclitaxel in all stages of breast cancer
Study, ClinicalTrials.gov 
identifier
Phase Planned N Patient population or stage 
of disease
Regimen Primary endpoint
Early-stage (n = 4)
 GAIN-2, NCT01690702 [66] III 2886 High risk, after R0 resection Adjuvant epirubicin 150 mg/m2 
q2w × 3 cycles → nab-P 
260-330 mg/m2 × 3 cycles 
(TBD in run-in-phase) 
q2w → cyclophosphamide 
2000 mg/m2 q2w × 4 cycles
iDFS
EC q2w → docetaxel q2w
 ETNA, NCT01822314 III 632 High risk HER2− Neoadjuvant nab-P 125 mg/m2 
qw 3/4 × 4 cycles → AC, EC, 
or FEC × 4 cycles
pCR
Neoadjuvant paclitaxel 90 mg/m2 
qw 3/4 × 4 cycles → AC, EC, or 
FEC × 4 cycles
 NCT00618657 II 120 Stage I–III Neoadjuvant 
nab-P + carbo + trastuz for 
HER2+ qw × 12 weeks
PFS
Neoadjuvant nab-P + carbo 
qw × 12 cycles + bev 
q2w × 5 cycles for HER2−
 NCT02530489 II 37 TNBC nonmetastatic Neoadjuvant nab-P 100 mg/m2  
+ atezolizumab
pCR
 NCT02489448 I/II 61 Stage I–III TNBC Neoadjuvant dur-
valumab + nab-P qw × 12 
cycles → ddAC × 4 cycles
pCR (ypT0/Tis, ypN0)
Metastatic or advanced stage (n = 12)
 PERUSE, NCT01572038 [43] III 1500 HER2+ Trastuz + pertuzumab +  
taxane of choice
Safety
 IMpassion130, NCT02425891 III 350 Untreated locally advanced or 
metastatic TNBC
nab-P + atezolizumab PFS
nab-P + placebo
 tnAcity, NCT01881230 [48] II/III 790 TNBC Selected nab-P regimen from 
phase II portion (either nab- 
P 125 mg/m2 + gem 
1000 mg/m2 d1, 8 q3w or
nab-P 125 mg/m2 + carbo AUC 
2 d1, 8 q3w)
PFS
Gem 1000 mg/m2 + carbo AUC 
2 d1, 8 q3w
 SNAP, NCT01746225 [48] II 258 HER2− MBC Induction nab-P 125 mg/m2  
qw 3/4 × 3 cycles in all 
patients → randomization 
into 3 arms: nab-P  
150 mg/m2 q2w
ORR by RECIST v1.1
nab-P 100 mg/m2 qw 3/4
nab-P 75 mg/m2 qw
 NCT00733408 II 63 MBC Induction nab-P qw 3/4 + bev 
q2w → maintenance with 
bev q2w or q3w + erlotinib 
qd
PFS
 NCT01730833 II 50 Stage II–IV HER2+ LABC and 
MBC
Pertuzumab q3w + trastuz 
qw + nab-P qw
PFS
 NCT01463072 II 40 LABC or MBC in ≥65-year-old 
patients
nab-P qw 3/4 Tolerability





 NCT02379247 I/II 54 Locally recurrent BC or MBC PI3K inhibitor BYL719 + nab-P 
100 mg/m2 qw 3/4
Phase I, RP2D; phase II, ORR
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A number of ongoing trials are also evaluating nab-
paclitaxel in HER2-negative MBC. The phase II/III tnAc-
ity trial (NCT01881230) is comparing nab-paclitaxel plus 
gemcitabine with nab-paclitaxel plus carboplatin as first-
line treatment for metastatic TNBC. The phase II portion 
(N = 240) has 3 arms: nab-paclitaxel 125 mg/m2 plus gem-
citabine 1000 mg/m2 on days 1 and 8 q3w, nab-paclitaxel 
125 mg/m2 plus carboplatin area under the curve (AUC) 
of 2 days 1 and 8 q3w, and gemcitabine 1000 mg/m2 plus 
carboplatin AUC of 2 days 1 and 8 q3w (https://clinical-
trials.gov/ct2/show/NCT01881230, [47]). In the phase III 
portion (N = 550), the nab-paclitaxel plus gemcitabine or 
nab-paclitaxel plus carboplatin arm will be selected based 
on phase II trial results and compared with gemcitabine 
1000 mg/m2 plus carboplatin AUC of 2 q3w. The phase II 
SNAP trial (NCT01746225; planned N = 258) will evalu-
ate different schedules of first-line nab-paclitaxel for the 
treatment of HER2-negative MBC (https://clinicaltri-
als.gov/ct2/show/NCT01746225, [48]). All patients will 
receive induction nab-paclitaxel 125  mg/m2 qw 3/4 fol-
lowed by nab-paclitaxel 150 mg/m2 on days 1 and 15 of a 
28-day cycle, 100 mg/m2 qw 3/4, or 75 mg/m2 qw. PFS will 
be assessed as the primary endpoint. An ongoing phase I/
II study (NCT01938833; planned N  =  47) is evaluating 
the combination of nab-paclitaxel plus the histone dea-
cetylase inhibitor romidepsin in recurrent or metastatic 
HER2-negative inflammatory breast cancer [https://clini-
caltrials.gov/ct2/show/NCT01938833]. Results from the 
phase I portion (n  =  9) demonstrated that the regimen 
was well tolerated and resulted in an ORR of 33%, includ-
ing 1 complete response [49].
Discussion
Recent clinical data indicate that nab-paclitaxel is effec-
tive and safe across all stages of breast cancer. The results 
from trials in the neoadjuvant setting for early-stage 
TNBC or HER2-positive breast cancer were particularly 
encouraging. In TNBC, nab-paclitaxel monotherapy or 
in combination with other agents resulted in pCR rates 
ranging from 10.5 to 62%. In the phase III neoadjuvant 
GeparSepto trial, the largest difference in pCR was iden-
tified for patients with TNBC (nab-paclitaxel, 48.2% vs 
paclitaxel, 26.3%; P < 0.001), supporting the clinical bene-
fit of nab-paclitaxel in early-stage TNBC [11]. The unmet 
need for the treatment of TNBC lends greater impor-
tance to these findings. Patients with early-stage HER2-
positive breast cancer also benefited from nab-paclitaxel 
treatment. Neoadjuvant nab-paclitaxel combined with 
trastuzumab and carboplatin, anthracycline, or vinorel-
bine demonstrated pCR rates in the breast and lymph 
nodes ranging from 45 to 49%, which is comparable to 
those observed for other current neoadjuvant therapies 
[50]. In addition, neoadjuvant nab-paclitaxel resulted in 
breast-conserving surgery in 71 to 77.5% of patients with 
early-stage breast cancer.
In the phase III CALGB 40502 study, patients with MBC 
treated with first-line nab-paclitaxel plus bevacizumab 
achieved a median PFS of approximately 9  months and 
a median OS of 23.5 months [30]. For reference, patients 
with MBC who received nab-paclitaxel 260  mg/m2 
q3w as first- or later-line therapy in a phase III trial 
demonstrated a median time to tumor progression of 
5.3 months and a median OS of 15.0 months [5]. Neither 
PFS nor OS for the nab-paclitaxel plus bevacizumab arm 
of the CALGB 40502 trial was significantly different from 
that of the paclitaxel plus bevacizumab arm [30]. The 
150 mg/m2 dose of nab-paclitaxel was not optimal, with a 
higher percentage of patients in the nab-paclitaxel group 
developing hematologic and nonhematologic toxicities. 
Several ongoing trials are evaluating the potential clini-
cal benefit of nab-paclitaxel in patients with MBC, par-
ticularly the HER2-positive and TNBC subpopulations. 
AC doxorubicin + cyclophosphamide, AUC area under the curve, BC breast cancer, bev bevacizumab, carbo carboplatin, ddAC dose-dense AC, DLT dose-limiting 
toxicity, EC epirubicin + cyclophosphamide, FEC fluorouracil, epirubicin, and cyclophosphamide, gem gemcitabine, HER2 human epidermal growth factor receptor 2, 
iDFS invasive disease-free survival, is in situ, LABC locally advanced breast cancer, MBC metastatic breast cancer, MTD maximum tolerated dose, nab-P nab-paclitaxel, 
ORR overall response rate, pCR pathologic complete response, PD-L1 programmed death-ligand 1, PFS progression-free survival, PI3K phosphoinositide 3-kinase, 
q2w every 2 weeks, q3w every 3 weeks, qd daily, qw weekly, qw 3/4 first 3 of 4 weeks, R resection margin, RECIST Response Evaluation Criteria In Solid Tumors, RP2D 
recommended phase 2 dose, T primary tumor, TBD to be determined, T-DM1 trastuzumab emtansine, TNBC triple-negative breast cancer, trastuz trastuzumab, yp 
postneoadjuvant therapy




Phase Planned N Patient population or stage 
of disease
Regimen Primary endpoint
 NCT01938833 I/II 47 Metastatic inflammatory BC nab-P + romidepsin qw 3/4 MTD, PFS
 STELA, NCT02073916 [46] I/II 45 HER2+ MBC T-DM1 + lapatinib + nab-P MTD
 NCT02309177 I 138a Recurrent MBC and other solid 
tumor types
Nivolumab + nab-P 100  
mg/m2 qw 3/4a
DLTs, safety
Nivolumab + nab-P 260  
mg/m2 q3wa
Page 12 of 15Brufsky  Exp Hematol Oncol  (2017) 6:7 
Interim analyses from some of these trials have demon-
strated promising results; once final, the findings from 
these trials will provide further insights into the role of 
nab-paclitaxel for the treatment of breast cancer across 
treatment settings and patient subsets.
Recent efforts to maintain efficacy while limiting toxicity 
have focused on the optimization of nab-paclitaxel sched-
ule and dose. The safety profiles of nab-paclitaxel–based 
regimens in the recent studies included in this review 
were consistent with those in past studies, including the 
registrational phase III trial. The most common grade 3/4 
hematologic and nonhematologic adverse events associ-
ated with nab-paclitaxel were neutropenia and peripheral 
neuropathy, respectively. The majority of recent studies 
have examined weekly dosing, likely because an accumula-
tion of data in the metastatic setting suggests an advantage 
over every-3-week dosing in balancing efficacy and tolera-
bility. In addition, safety and treatment-exposure results of 
2 large trials (GeparSepto in the neoadjuvant setting and 
CALGB 40502 in the metastatic setting) have suggested 
that nab-paclitaxel may be more feasible at a starting dose 
of 125 mg/m2 compared with 150 mg/m2 [11, 30].
Future of nab‑paclitaxel in breast cancer: nab‑paclitaxel 
and immune therapy
In addition to the ongoing trials discussed above, there is 
interest in combining nab-paclitaxel with immuno-oncol-
ogy agents (Table  3). Chemotherapy-induced cytotoxic-
ity has been shown to activate the immune response and 
to release tumor antigens from cancer cells [51, 52]. Pre-
clinical data from mouse models of multiple solid tumor 
types suggested potential synergy between chemotherapy 
and immune checkpoint inhibitors [53, 54]. Recent clini-
cal data indicated that combining nab-paclitaxel with 
checkpoint inhibitors may be safe and effective in MBC. 
A phase Ib study of atezolizumab, a programmed death 
ligand 1 (PD-L1) inhibitor, combined with nab-paclitaxel 
qw (NCT01633970) demonstrated activity in 24 efficacy-
evaluable patients with metastatic TNBC (ORR 70.8%; 
stable disease in 20.8%) [55]. Five patients (16%) discon-
tinued nab-paclitaxel due to toxicity (3 for peripheral 
neuropathy [1 each for grades 1, 2, and 3] and 1 each for 
fatigue and asthenia [both grade 2]). nab-Paclitaxel plus 
atezolizumab is currently being compared with nab-pacli-
taxel plus placebo as a first-line treatment for metastatic 
TNBC in the randomized phase III IMpassion130 trial 
(NCT02425891; Table  3) (https://clinicaltrials.gov/ct2/
show/NCT02425891, [56]). The PD-1 inhibitor nivolumab 
is also being evaluated in combination with nab-pacli-
taxel in MBC in an ongoing phase I trial (NCT02309177; 
planned N  =  138) [https://clinicaltrials.gov/ct2/show/
NCT02309177]. The combination of atezolizumab and 
nab-paclitaxel is also being evaluated as a neoadjuvant 
regimen for the treatment of early-stage TNBC in an 
ongoing phase II trial (NCT02530489; planned N  =  37) 
[https://clinicaltrials.gov/ct2/show/NCT02530489] and a 
phase III trial (NeoTRIPaPDL1; NCT02620280 [nab-pacli-
taxel plus carboplatin ± atezolizumab]; planned N = 272) 
[https://clinicaltrials.gov/ct2/show/NCT02620280]. Simi-
larly, the PD-L1 inhibitor durvalumab combined with 
nab-paclitaxel is being examined as neoadjuvant ther-
apy for early-stage TNBC in an ongoing phase I/II trial 
(NCT02489448; planned N  =  61) [https://clinicaltrials.
gov/ct2/show/NCT02489448]. Results from these trials 
will provide further rationale for combining nab-pacli-
taxel with immune therapies as an exciting new treatment 
approach for early-stage or metastatic breast cancer.
Conclusions
In addition to demonstrated efficacy in the already estab-
lished setting of MBC, nab-paclitaxel appears to be an effec-
tive and well-tolerated neoadjuvant therapy for patients 
with early-stage breast cancer, particularly the HER2-pos-
itive and TNBC subgroups. Ongoing trials are evaluating 
nab-paclitaxel in all stages and subtypes of breast cancer. 
One anticipated future role of nab-paclitaxel is as a back-
bone chemotherapy, and ongoing trials of nab-paclitaxel 
combined with immune checkpoint inhibitors are particu-
larly exciting, as these may provide more effective treatment 
regimens for early-stage and metastatic breast cancer.
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